Fig. 2
From: Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial
Primary outcome measure. Estimated mean group changes for clinical scores. Estimated mean group changes from baseline (W0) in the CDR-SB following 12 weeks (W12), 24 weeks (W24) 36 weeks (W36) and 52 weeks (W52) of PC-rTMS and sham-rTMS. Y-axis of each outcome was adapted in order to considering all depicted descending trend as a worsening. In the CDR-SB scale; scores are obtained by summing each of the domain box scores, with scores ranging from 0 to 18, with higher scores indicating worse cognition. Baseline is plotted at Week 0, which is the baseline measurement before the first rTMS session. Error bars indicate standard errors